The industry is in a difficult position. It is caught between wanting to satisfy the demands of the Trump administration while protecting its most important market and having minimal control over its negotiations with other countries. In other words, it is part stakeholder, participant and spectator.
Why not construct an off-ramp based on what you were going to do anyway?
June 15, 2025 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Taylor confirms Anne Ruston will retain health portfolio in opposition reshuffle
February 17, 2026 - - Latest News -
Minister confirms PBS listing for new cystic fibrosis therapy and funded access to other medicines
February 16, 2026 - - Latest News -
Director pay rises across ASX healthcare sector, but gender balance remains uneven
February 16, 2026 - - Latest News -
Life sciences sector unites to advance women’s leadership at landmark 2026 events
February 16, 2026 - - Latest News -
New imaging agent shows stronger detection of recurrent prostate cancer in head-to-head trial
February 16, 2026 - - Australian Biotech -
Medibank funding expansion signals momentum for Emyria’s mental health model
February 16, 2026 - - Latest News -
IMF pours cold water on fears of US pharmaceutical tariffs as pressures shift to care spending
February 16, 2026 - - Latest News

